HR (Venoruton1000, Paroven, 0-[beta-hydroxyethyl]-rutosides) vs. Daflon 500 in Chronic Venous Disease and Microangiopathy: An Independent Prospective, Controlled, Randomized Trial

Belcaro, Gianni; Cesarone, M. R.; Bavera, P; Ricci, A.; Renton, Sophie; León, M.L. Villalobos; Ippolito, E.; Dugall, Mark; Acerbi, G.

doi:10.1177/107424840200700303

Cited by 17 publications

(14 citation statements)

References 21 publications

(23 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Venoruton, a compound that has been widely used in venous disease, has been shown to have a high degree of safety and to be particularly active on edema, swelling, and signs and symptoms of CVI (27)(28)(29)(30)(31). This pilot study indicates the effects of Venoruton in decreasing the number of circulating endothelial cells in venous disease, suggesting new modes of action of this compound.…”

Section: Resultsmentioning

confidence: 99%

Circulating Endothelial Cells in Venous Blood as a Marker of Endothelial Damage in Chronic Venous Insufficiency: Improvement with Venoruton

Cesarone¹,

Belcaro²,

Pellegrini³

et al. 2006

J Cardiovasc Pharmacol Ther

View full text Add to dashboard Cite

Damage to endothelial cells is common in vascular disorders and in reactions associated with transplantation. An elevated number of circulating endothelial cells indicates the extent of endothelial damage in a variety of disorders. In chronic venous insufficiency (CVI), the number of endothelial cells is abnormally increased, and this can be considered an important indication of endothelial damage. A group of 23 subjects with two levels of CVI (severe and very severe with previous ulcerations) with an increased endothelial cell count (seen by microscopy) was studied and treated for 4 weeks with oral Venoruton (0-[beta-hydroxyethyl]-rutosides) (1 g/day) to evaluate the effects of treatment on the circulating endothelial cells in blood taken from a peripheral leg vein. The controls comprised two groups with comparable age and sex distribution, one of healthy individuals and one of CVI subjects. After 4 weeks, a significant decrease was noted in endothelial cells both in subjects with CVI and in those with very severe CVI with previous ulcerations. This study suggests that endothelial cells may play a significant role in venous disease, being both an indication of severe disease and a further problem in itself. The use of Venoruton appears to decrease the number of circulating endothelial cells. This suggests an important role of this compound in protecting the endothelium and offers new potentially important therapeutic options that are not limited only to venous disease.

show abstract

Section: Resultsmentioning

confidence: 99%

Circulating Endothelial Cells in Venous Blood as a Marker of Endothelial Damage in Chronic Venous Insufficiency: Improvement with Venoruton

Cesarone¹,

Belcaro²,

Pellegrini³

et al. 2006

J Cardiovasc Pharmacol Ther

View full text Add to dashboard Cite

show abstract

“…Oxerutin has been shown to have a high degree of safety and to be particularly active on oedema, swelling, and signs and symptoms of CVI. 32,34–36…”

Section: Discussionmentioning

confidence: 99%

Calcium dobesilate and oxerutin: effectiveness of combination therapy

Akbulut

2010

Phlebology

View full text Add to dashboard Cite

show abstract

“…One observational study 62 and four RCTs 24,46,84,86 reported that MPFF was well tolerated. One observational study 59 and three RCTs 71,75,85 reported good compliance with MPFF. Five observational studies 52,53,59,61,81 and two RCTs 85,86 reported no side effects with MPFF use.…”

Section: Adverse Effectsmentioning

confidence: 98%

Micronized purified flavonoid fraction for the treatment of chronic venous insufficiency, with a focus on postthrombotic syndrome: A narrative review

Diendéré

Galanaud

et al. 2021

Research and Practice in Thrombosis and Haemostasis

View full text Add to dashboard Cite

show abstract

HR (Venoruton1000, Paroven, 0-[beta-hydroxyethyl]-rutosides) vs. Daflon 500 in Chronic Venous Disease and Microangiopathy: An Independent Prospective, Controlled, Randomized Trial

Abstract: Venous microangiopathy was improved by the treatment with Venoruton. The comparison with Daflon indicates that HR is comparatively more effective both on microcirculatory parameters and on signs and symptoms.

Cited by 17 publications

References 21 publications

Circulating Endothelial Cells in Venous Blood as a Marker of Endothelial Damage in Chronic Venous Insufficiency: Improvement with Venoruton

Circulating Endothelial Cells in Venous Blood as a Marker of Endothelial Damage in Chronic Venous Insufficiency: Improvement with Venoruton

Calcium dobesilate and oxerutin: effectiveness of combination therapy

Micronized purified flavonoid fraction for the treatment of chronic venous insufficiency, with a focus on postthrombotic syndrome: A narrative review

Contact Info

Product

Resources

About